It’s raining mergers and investments in Hyderabad. More so in the pharma segment. With a strong pharma base, the city is attracting investments to the tune of hundreds of crores. One such latest investment comes from market leader Piramal Pharma that invested Rs 101.77 crore in city-based Yapan Bio to augment the capabilities of its contract development and manufacturing organization (CDMO) business.
As of now, the Mumbai-based company has acquired a 27.78 stake in Yapan as a result of the investment. The current investment will help Piramal Pharma to strengthen PPS or Piramal Pharma Solutions, its CDMO business, by widening its service offerings.
Yapan Bio provides process development, scale-up, and cGMP compliant manufacturing of vaccines and biologics/ bio-therapeutics, including high containment product classes (up to BSL 2+), recombinant vaccines, RNA/ DNA vaccines, gene therapies, monoclonal antibodies, therapeutic proteins, and other complex biologics.
Piramal Pharma chairperson Nandini Piramal shares that the expertise found at Yapan will help Piramal provide existing customers with wider capabilities for developing and manufacturing large molecules. She adds that the investment will further support their growth strategy.
This investment, coupled with market-leading capabilities of Grangemouth, UK site in antibody-drug conjugations and our sterile fill capabilities in Lexington, USA, demonstrates their commitment to growing their service offerings in large molecule CDMO space, says Piramal Pharma Solutions CEO Peter DeYoung.